排名前五的靶点	数量

fungal CYP51A1(真菌细胞色素P450家族成员51)	1
H1 receptor x Platelet-activating factor	1
SUR(磺酰脲受体)	1
COX-1(环氧化酶-1)	1
COX-2(环氧化酶-2)	1

关联

项与 Noucor Health SA 相关的药物

Rupatadine Fumarate

富马酸卢帕他定

靶点

H1 receptor x Platelet-activating factor

作用机制

H1 receptor拮抗剂 [+1]

在研机构

Medexus Pharmaceuticals, Inc. [+6]

原研机构

Noucor Health SA

在研适应症

湿疹 [+6]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2013-05-09

Glisentide

格列生脲

靶点

SUR

作用机制

SUR激动剂

在研机构

Noucor Health SA

原研机构

Noucor Health SA

在研适应症

2型糖尿病 [+1]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

西班牙

首次获批日期1997-01-27

Flutrimazole

氟曲马唑

靶点

fungal CYP51A1

作用机制

fungal CYP51A1抑制剂

在研机构

江苏远恒药业有限公司 [+2]

原研机构-

在研适应症

足癣 [+2]

非在研适应症

皮肤念珠菌病

最高研发阶段批准上市

首次获批国家/地区

西班牙

首次获批日期1995-03-10

项与 Noucor Health SA 相关的临床试验

NCT06199128 / CompletedN/A

Evaluation of the Efficacy and Safety of the Local Treatment of Carboxymethyl Beta-glucan and Polycarbophil in Patients With Normal Cytology/ASCUS/LSIL (CIN1) With HPV+ PCR Determination

Prospective, Controlled, Multicentre, Real Clinical Practice Study. Effectiveness of Carboxymethyl β-Glucan treatment in high-risk HPV+ patients

开始日期2022-09-22

申办/合作机构

Uriach Consumer Healthcare SL

NCT05459272 / RecruitingN/A

A Randomized, Placebo-Controlled Clinical Trial on a Dietary Supplement Containing Melatonin and Herbal Products to Improve Sleep Quality in Subjects With Insomnia Problems

A randomized, double-blind, placebo-controlled clinical trial on the ability of a dietary supplement containing melatonin and herbal products to improve sleep quality in subjects with insomnia problems with a 15-day follow-up period.

开始日期2022-07-10

申办/合作机构

Uriach Consumer Healthcare SL

NCT05356143 / Completed临床1期

A Single-Dose, Partial-Replicate, Pharmacokinetic, and Comparative Bioavailability Study of Rupatadine 10 mg Tablets and Clarinex® 5 mg Tablets Under Fasting Conditions

This is an open-label, single-dose, randomized, three-period, two-treatment, threesequence, crossover, PK, partial replicate, and comparative bioavailability study. This study may be conducted in groups. The same protocol requirements and procedures will be followed for each group.

开始日期2021-12-02

申办/合作机构

Grupo J Uriach SL

100 项与 Noucor Health SA 相关的临床结果

登录后查看更多信息

0 项与 Noucor Health SA 相关的专利（医药）

登录后查看更多信息

项与 Noucor Health SA 相关的文献（医药）

2008-07-01·The Journal of clinical endocrinology and metabolism2区 · 医学

Salicylates Increase Insulin Secretion in Healthy Obese Subjects

2区 · 医学

Article

作者: Ropero, Ana-Belén ; Pérez, Iñaki ; Fernández-Real, José-Manuel ; Ricart, Wifredo ; Bassols, Judit ; Gomis, Ramón ; Nadal, Angel ; Casamitjana, Roser ; Piquer, Sandra ; Arnaiz, Eva ; López-Bermejo, Abel

Abstract:

Context: Conflicting results on the effects of salicylates on glucose tolerance in subjects with normal glucose tolerance or type 2 diabetes have been reported.Objective: The objective of the study was to investigate the effects of a salicylate derivative (triflusal) on insulin sensitivity and insulin secretion.Design, Setting, and Participants: This was a double-blind, randomized, crossover study with three treatment periods corresponding to two dose levels of triflusal and placebo in healthy obese subjects.Main Outcome Measures: Insulin sensitivity and insulin secretion, evaluated through frequently sampled iv glucose tolerance test that was performed after each treatment period, were measured. Insulin secretion was also evaluated in vitro in mice and human islets of Langerhans.Results: The administration of triflusal led to decreased fasting serum glucose concentration in the study subjects. Insulin sensitivity did not significantly change after each treatment period. Insulin secretion, however, significantly increased in a dose-dependent fashion after each triflusal treatment period. The administration of 800 μm of the main triflusal metabolite to whole mice islets of Langerhans led to a sustained increase in intracellular calcium concentration level. This was followed by a significantly increase in insulin secretion. In human islets, 200 μm of 2-hydroxy-4-trifluoromethylbenzoic acid was sufficient to increase insulin release.Conclusions: The administration of a salicylate compound led to lowering of serum glucose concentration. We suggest that this effect was mediated through increased insulin secretion induced by salicylate directly on the β-cell.

2006-01-31·European journal of medical research3区 · 医学

Efficacy and tolerability of a spray with Salvia officinalis in the treatment of acute pharyngitis - a randomised, double-blind, placebo-controlled study with adaptive design and interim analysis.

3区 · 医学

ArticleOA

作者: Kehrl, W ; Lehnfeld, R ; Hubbert, Michael ; Sievers, H

OBJECTIVE:

This randomised, double-blind, parallel group phase II/III study with adaptive two-stage design and interim analysis compared the efficacy and tolerability of spray (containing a Salvia officinalis fluid extract) against placebo in the treatment of patients with acute viral pharyngitis. -

STUDY PARTICIPANTS:

in two study parts, a total of 286 patients with subjective and objective evidence of pharyngitis were randomized. In the first study part 122 patients were enrolled. In the second study part 164 patients were included. The treatment duration per patient was 3 days, including one baseline visit and one final visit. -

MAIN OUTCOME MEASURES:

Area under Curve for change of throat pain intensity (spontaneous pain), documented every 15 minutes within the first 2 hours after the first application as compared to baseline using a visual analog scale (VAS 100 mm). -

RESULTS:

Following the interim analyses of the first study part the 15 % spray containing 140 microl sage extract per dose was the most promising preparation for the second study part (main study) whereas for the 30% and the 5% preparation results made superiority over placebo unlikely in the final analysis. Overall, the 15 % spray was significantly superior to placebo for the primary efficacy variable with regard to a reduction of the throat pain intensity score. Only minor side effects such as dry pharynx or burning of mild intensity were seen. -

CONCLUSIONS:

The efficacy and tolerability profile of a 15 % sage spray indicated that this preparation provides a convenient and safe treatment for patients with acute pharyngitis. A symptomatic relief occurred within the first two hours after first administration and was statistically significantly superior to placebo.

2005-01-01·Microbial Processes and Products

Strategies for Large-Scale Production of Recombinant Proteins in Filamentous Fungi

作者: Heidi Sisniega ; José-Luis del Río ; María-José Amaya ; Ignacio Faus

A review with methods.A pilot-plant process for the production of a recombinant sweet-tasting protein in the filamentous fungus Aspergillus awamori is described.Each step of the scale-up and downstream processes (concentration, diafiltration and ion-exchange chromatog.) for the production and purification of the secreted recombinant protein is detailed.

项与 Noucor Health SA 相关的新闻（医药）

2024-08-13

·药融云

华海拿下3亿+抗过敏药，两大品种同日获批！

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 8月7日，据浙江华海药业发布公告，其公司申报的富马酸卢帕他定片和维格列汀片均以仿制4类报产同日获批，视同过评。今年以来，浙江华海药业（含子公司）有16款品种获批。截图来源：企业公告富马酸卢帕他定片最早由J. Uriach y Compañía, S.A.研发。为第二代抗组胺药物，是一种长效、选择性外周H1受体拮抗剂。用于成年人和青少年（大于12岁）过敏性鼻炎和荨麻疹的对症治疗。据药融云数据库显示，2023年富马酸卢帕他定片在全国院内市场的销售额达3.4亿元，同比增长达11.02%。截图来源：药融云全国医院销售数据库目前，富马酸卢帕他定片有8家药企拥有生产批文，浙江华海药业、北京四环科宝制药、合肥恩瑞特药业、扬子江药业集团江等6家国内药企均已过评。截图来源：药融云过评药品汇总数据库维格列汀片是一种高效的选择性二肽基肽酶4（DPP-4）抑制剂，用于治疗2型糖尿病。据药融云数据库显示，该品种在2023年全国院内市场的销售额超5千万元。目前，维格列汀片有29家药企拥有生产批文，浙江华海药业、成都恒瑞制药、齐鲁制药、仁合益康集团等28家国内药企均已过评。截图来源：药融云过评药品汇总数据库今年以来，华海药业已有富马酸卢帕他定片、富马酸喹硫平片、托拉塞米片、注射用盐酸表柔比星等16款产品获批，涵盖呼吸系统药物、神经系统药物、心血管系统药物、消化系统与代谢药物等多个领域。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“CSCO”，获取2023CSCO指南后台回复关键词“ASCO”，获取2023ASCO分癌种摘要后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复关键词“医保”，获取2022年医保目录联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

ASCO会议上市批准CSCO会议一致性评价

2023-02-27

·GlobeNewswire-Health Care

Changes in the governance of NFL Biosciences

Changes in the governance of NFL Biosciences NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, and in particular NFL-101, its drug candidate for smoking cessation, announces the appointment of Ignacio Faus, current CEO, as Chairman of the Board of Directors. Appointment of Dr. Ignacio Faus as Chairman of the Board of Directors At its meeting on February 27, 2023, the Board of Directors of NFL Biosciences acknowledged the wish of Mr. Joël Besse to step down as Chairman and member of the Board of Directors in order to fully devote himself to his activity as investor in unlisted startup companies in the life sciences sector. Dr. Ignacio Faus, currently Director and Chief Executive Officer of NFL Biosciences, has been appointed Chairman of the Board of Directors and now becomes Chairman and Chief Executive Officer, replacing Mr. Joël Besse. Having joined NFL Biosciences in 2019 as an investor, Dr. Ignacio Faus joined the management team in early 2021. He has 27 years of experience in large and medium-sized pharmaceutical companies and in private and public biotech companies: Bristol Myers Squibb, Grupo Uriach, Ferrer and co-founder in 2006 and CEO of Palau Pharma (divested in 2013). In recent years, Ignacio Faus has also been a Director of several private and public biotech companies as well as private equity funds in Europe and the United States. He holds a PhD in Biochemistry (Indiana University, USA) and an MBA in Entrepreneurship and Finance from the Kellogg School of Management (Northwestern University, USA). Ignacio Faus, Chairman and CEO of NFL Biosciences, commented: “I am very honored to take over as Chairman of the Board of NFL Biosciences and would like to sincerely thank Joël Besse for his operational and financial involvement since 2018. After his support during the IPO, the company now has a secure financial position for the next 18 months, following the recently concluded capital increase and the financing from Bpifrance.” About NFL Biosciences NFL Biosciences is a biopharmaceutical company based in the Montpellier area which develops botanical drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders. The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com Contacts Bruno Lafont – info@nflbiosciences.com - +33 4 11 93 76 67 Agence Calyptus – nflbio@calyptus.net - +33 1 53 65 68 68 Attachment NFLBiosciences_CP_Gouvernance_ENG

高管变更

100 项与 Noucor Health SA 相关的药物交易

登录后查看更多信息

100 项与 Noucor Health SA 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

氟曲马唑 ( fungal CYP51A1 )	花斑癣更多	批准上市
格列生脲 ( SUR )	2型糖尿病更多	批准上市
UR-14048 ( COX-2 )	急性疼痛更多	临床前
富马酸卢帕他定 ( H1 receptor x Platelet-activating factor )	慢性荨麻疹更多	终止
Dersalazine ( PAF receptor )	溃疡性结肠炎更多	终止